Brief: Zevra Therapeutics Announces U.S. Commercial Availability Of Miplyffa For Treatment Of Niemann-Pick Disease Type C
21/11/2024 21:52
Nov 21 (Reuters) - Zevra Therapeutics Inc ZVRA.O :
* ZEVRA THERAPEUTICS ANNOUNCES U.S. COMMERCIAL AVAILABILITY
OF
MIPLYFFA™ (ARIMOCLOMOL) FOR TREATMENT OF NIEMANN-PICK DISEASE
TYPE C
Source text: ID:nGNX485g4M
Further company coverage: ZVRA.O
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor